Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring
WM van Oostveen, ECM de Lange - International journal of molecular …, 2021 - mdpi.com
Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …
affecting many individuals worldwide with no effective treatment to date. AD is characterized …
Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …
considering the disease as a continuum. Thanks to evolving biomarker research and …
Multimodal deep learning for Alzheimer's disease dementia assessment
Worldwide, there are nearly 10 million new cases of dementia annually, of which
Alzheimer's disease (AD) is the most common. New measures are needed to improve the …
Alzheimer's disease (AD) is the most common. New measures are needed to improve the …
Development and validation of an interpretable deep learning framework for Alzheimer's disease classification
Alzheimer's disease is the primary cause of dementia worldwide, with an increasing
morbidity burden that may outstrip diagnosis and management capacity as the population …
morbidity burden that may outstrip diagnosis and management capacity as the population …
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …
Plasma phospholipids identify antecedent memory impairment in older adults
Alzheimer's disease causes a progressive dementia that currently affects over 35 million
individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no …
individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no …
Metabolic dysregulation contributes to the progression of Alzheimer's disease
X Yan, Y Hu, B Wang, S Wang, X Zhang - Frontiers in neuroscience, 2020 - frontiersin.org
Alzheimer's disease (AD) is an incurable neurodegenerative disease. Numerous studies
have demonstrated a critical role for dysregulated glucose metabolism in its pathogenesis …
have demonstrated a critical role for dysregulated glucose metabolism in its pathogenesis …
Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts
PM Rossini, R Di Iorio, F Vecchio, M Anfossi… - Clinical …, 2020 - Elsevier
Alzheimer's disease (AD) is the most common neurodegenerative disease among the
elderly with a progressive decline in cognitive function significantly affecting quality of life …
elderly with a progressive decline in cognitive function significantly affecting quality of life …
Insulin resistance and Alzheimer's disease: bioenergetic linkages
BJ Neth, S Craft - Frontiers in aging neuroscience, 2017 - frontiersin.org
Metabolic dysfunction is a well-established feature of Alzheimer's disease (AD), evidenced
by brain glucose hypometabolism that can be observed potentially decades prior to the …
by brain glucose hypometabolism that can be observed potentially decades prior to the …
Brain fluorodeoxyglucose (FDG) PET in dementia
T Kato, Y Inui, A Nakamura, K Ito - Ageing research reviews, 2016 - Elsevier
The purpose of this article is to present a selective and concise summary of
fluorodeoxyglucose (FDG) positron emission tomography (PET) in dementia imaging. FDG …
fluorodeoxyglucose (FDG) positron emission tomography (PET) in dementia imaging. FDG …